Latest / Stock Movers / Ryanair Falls, PolyPeptide Gains, Segro Slips
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News, The.
- 0:08Speaker 2: Stock Movers Report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Well, let's take a look at some stocks on the
- 0:18Speaker 3: move today in Europe. I'm Stephen Carroll and I'm joined
- 0:20Speaker 3: by Bloomberg's Breaking News editor Louise Moon.
- 0:22Speaker 4: Louise, good morning.
- 0:23Speaker 3: Let's start then with Ryanair and a hit to their profits.
- 0:27Speaker 1: Indeed, yes, shares down this morning for Ryanair as much
- 0:30Speaker 1: as about almost eight percent this morning.
- 0:33Speaker 4: As you say hit the profits.
- 0:34Speaker 1: Profits fell thirty four percent in the first quarter and
- 0:38Speaker 1: missed estimates as well. Essentially this is all down to
- 0:41Speaker 1: the impacts from a war in the Middle East, so twofold,
- 0:44Speaker 1: driving up oil prices and weakening demand for travel.
- 0:49Speaker 4: So taking both of them.
- 0:51Speaker 1: Oil prices obviously that's fuel costs, and then demand has
- 0:54Speaker 1: been weakening because travelers essentially are hesitant booking trips at
- 0:58Speaker 1: the last minute. That therefore has forced Ryanair to cut
- 1:02Speaker 1: their fares their sum affairs and Summer is the peak
- 1:06Speaker 1: travel seasons that's really hitting their profits, as I say,
- 1:09Speaker 1: down thirty four percent. They also said going into the
- 1:12Speaker 1: second half of the year, they have no visibility, so
- 1:14Speaker 1: they held off issuing guidance for full year profits. So
- 1:18Speaker 1: across the board, a big hit to Ryanair. It's the
- 1:21Speaker 1: first kind of major European character report on its first quarter.
- 1:26Speaker 1: So despite you know, despite the fact that it's a
- 1:28Speaker 1: bit of a well trodden story that the war in
- 1:30Speaker 1: the Middle East has really hit the aviation sector, this
- 1:33Speaker 1: does give a bit of an insight into how and
- 1:36Speaker 1: the extent of the challenges still remaining. Got to be
- 1:40Speaker 1: said though, despite the analyst is saying that the long
- 1:42Speaker 1: term thesis does remain unchanged. So Ryanair is effectively has
- 1:46Speaker 1: a debt free balance sheet, It's order book is relatively strong,
- 1:49Speaker 1: it's got a strong market position. But the impact of
- 1:52Speaker 1: the Middle East, that's what's driving the profit for and
- 1:54Speaker 1: driving the share reaction this morning as well.
- 1:57Speaker 3: Yeah, indeed a very interesting one given especially Rhino doesn't
- 2:00Speaker 3: operates routes in the Middle East, so of course it
- 2:02Speaker 3: makes them the knock on effects more obvious in their results.
- 2:05Speaker 3: So let's go to Switzerland next and all cash deal
- 2:08Speaker 3: for the contract drug maker Polypeptide.
- 2:11Speaker 4: Yes, impacting their shares.
- 2:13Speaker 1: Shares about five percent this morning, sod but being brought
- 2:15Speaker 1: by a South Korean company called Samsung Biologics. This is,
- 2:18Speaker 1: as you say, in all cash deal values polypeptide at
- 2:22Speaker 1: about one point five billion Swiss francs.
- 2:23Speaker 4: That's about one point eight billion US dollars.
- 2:26Speaker 1: It represents a premium if you compare it to their
- 2:30Speaker 1: last clothes on Friday, of about six percent. But if
- 2:33Speaker 1: you compare it actually to their their stock price when
- 2:37Speaker 1: there were market rumors there were first market roomors first
- 2:39Speaker 1: started about potential takeover, it's forty percent premium, so kind
- 2:43Speaker 1: of unsurprising the shares up on the news for Samsung Biologics.
- 2:47Speaker 1: It's essentially it's expanding its manufacturing capabilities.
- 2:51Speaker 4: So polypeptide has.
- 2:53Speaker 1: Had a bit of a turnaround and it's been ramping
- 2:55Speaker 1: up its new facilities, which has attracted take of interest
- 2:58Speaker 1: not just from the South Korean company but also from
- 3:01Speaker 1: private equity funds. And it all comes in the wider
- 3:04Speaker 1: context of drug makers. There's more demand from drug makers
- 3:07Speaker 1: for polypeptide based medicine. So this is to treat treatments
- 3:11Speaker 1: for obese tea and others as well. So a big
- 3:15Speaker 1: deal there for the Swiss company, and that is due
- 3:17Speaker 1: to complete towards the end of the year.
- 3:20Speaker 3: Okay, And we've also been looking at Segro rejecting a
- 3:23Speaker 3: third bid from pro largest her investors reacting.
- 3:26Speaker 1: Yeah, some more big m and a news shares slipping
- 3:29Speaker 1: in terms of investor reaction for Segro. That's dragging down
- 3:32Speaker 1: the foot six hundred in London. So Segro is obviously
- 3:35Speaker 1: the warehouse landlord listed here in London, as you say,
- 3:38Speaker 1: rejected a third proposal from Prologust, and that was last
- 3:41Speaker 1: week that would have valued it at about thirteen point
- 3:44Speaker 1: five billion pounds, So it's a big deal. And essentially
- 3:48Speaker 1: what's happened this morning is that Prologus have come public
- 3:52Speaker 1: that they've they've announced that this happened, that it was rejected,
- 3:56Speaker 1: essentially trying to get shareholders on site. So as I say,
- 3:59Speaker 1: this is the third proposal, the difference being that Prologust
- 4:04Speaker 1: has offered some sweetness. So for example, they're saying that
- 4:07Speaker 1: if this does go through, they would explore a secondary
- 4:09Speaker 1: listing in London if investors wanted that there was enough.
- 4:12Speaker 4: Demand for that.
- 4:13Speaker 1: But yeah, they've gone public trying to persuade shareholders that
- 4:17Speaker 1: both sides have been had a bit of a war
- 4:19Speaker 1: of words I guess you could say Segro saying you
- 4:22Speaker 1: know that they've got the capabilities to go through their
- 4:25Speaker 1: plans of building a lot of data centers, whereas Prologus
- 4:30Speaker 1: is saying that they're understating how much money and execution
- 4:33Speaker 1: is needed to do that.
- 4:35Speaker 4: So this is still ongoing.
- 4:37Speaker 1: The deadline for an actual firm offer is July twenty seconds.
- 4:40Speaker 1: We're keeping an eye out as to what will happen,
- 4:43Speaker 1: and Segros has since come out and said that they
- 4:45Speaker 1: would engage if there was an improved bid, So we're
- 4:48Speaker 1: keeping a close eye as that.
- 4:50Speaker 4: Warren words and m and a saga drags on.
- 4:53Speaker 2: The Stock Movers report from Bloomberg Radio. Check back with
- 4:57Speaker 2: us throughout the day for the latest roundup of companies
- 5:00Speaker 2: making news on Wall Street and for the latest market
- 5:03Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 5:07Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 5:11Speaker 2: the Bloomberg Business app.